Idioma:

Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000

Schrappe, M. ; Möricke, A. ; Reiter, A. ; Henze, G. ; Welte, K. ; Gadner, H. ; Ludwig, W.-D. ; Ritter, J. ; Harbott, J. ; Mann, G. ; Klingebiel, T. ; Gruhn, B. ; Niemeyer, C. ; Kremens, B. ; Niggli, F. ; Debatin, K.-M. ; Ratei, R. ; Stanulla, M. ; Beier, R. ; Cario, G. ; Schrauder, A. ; Zimmermann, M.

Klinische Padiatrie, 2013-05, Vol.225 (S 01), p.S62-S72 [Periódico revisado por pares]

Stuttgart · New York: Georg Thieme Verlag KG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000
Autor: Schrappe, M. ; Möricke, A. ; Reiter, A. ; Henze, G. ; Welte, K. ; Gadner, H. ; Ludwig, W.-D. ; Ritter, J. ; Harbott, J. ; Mann, G. ; Klingebiel, T. ; Gruhn, B. ; Niemeyer, C. ; Kremens, B. ; Niggli, F. ; Debatin, K.-M. ; Ratei, R. ; Stanulla, M. ; Beier, R. ; Cario, G. ; Schrauder, A. ; Zimmermann, M.
Assuntos: Antineoplastic Combined Chemotherapy Protocols - history ; Asparaginase - history ; Child ; Cyclophosphamide - history ; Cytarabine - history ; Daunorubicin - history ; Europe ; Germany ; History, 20th Century ; History, 21st Century ; Humans ; Medical Oncology - history ; Mercaptopurine - history ; Methotrexate - history ; Pediatrics - history ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - history ; Prednisone - history ; Randomized Controlled Trials as Topic - history ; Vincristine - history ; Zum 80. Geburtstag von Prof. Riehm
É parte de: Klinische Padiatrie, 2013-05, Vol.225 (S 01), p.S62-S72
Descrição: Abstract Between 1981 and 2000, 6 609 children (<18 years of age) were treated in 5 consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria, and Switzerland. Probability of 10-year event-free survival (survival) improved from 65% (77%) in study ALL-BFM 81–78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.
Editor: Stuttgart · New York: Georg Thieme Verlag KG
Idioma: Inglês;Alemão

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000

Stuttgart · New York: Georg Thieme Verlag KG

Buscando em bases de dados remotas. Favor aguardar.